Amylyx Pharmaceuticals Inc. and NuScale Power Corporation represent two distinct sectors of the equity market, with Amylyx focusing on neurodegenerative disease therapeutics and NuScale specializing in modular nuclear reactor technology. As of late 2024, Amylyx is managing the commercial transition of its portfolio following the withdrawal of its ALS treatment, while NuScale continues to navigate the regulatory and developmental milestones required to bring small modular reactor (SMR) technology to the commercial energy grid.
Amylyx Pharmaceuticals: Clinical and Commercial Status
Amylyx Pharmaceuticals (NASDAQ: AMLX) has undergone a significant shift in its business strategy. In April 2024, the company announced it would voluntarily withdraw its amyotrophic lateral sclerosis (ALS) drug, Relyvrio, from the U.S. and Canadian markets following the failure of a Phase 3 trial to meet its primary endpoints, according to a company press release.
The company is now prioritizing its pipeline, specifically focusing on AMX0035 for the treatment of Wolfram syndrome and progressive supranuclear palsy (PSP). Investors and analysts monitor the company’s cash runway and clinical trial results as primary indicators of its long-term viability. According to the company’s second-quarter 2024 financial results, Amylyx held approximately $320.7 million in cash, cash equivalents, and investments as of June 30, 2024.
NuScale Power: Energy Sector Development
NuScale Power (NYSE: SMR) operates in the clean energy sector, specifically designing small modular reactors (SMRs). Unlike traditional nuclear plants, NuScale’s VOYGR power plant technology is designed to be scalable and factory-built. The company’s financial and operational progress is tied closely to the U.S. Nuclear Regulatory Commission (NRC) certification processes and agreements with potential utility customers.
The company has faced challenges regarding project viability. In late 2023, NuScale and the Utah Associated Municipal Power Systems (UAMPS) mutually agreed to terminate the Carbon Free Power Project, citing rising costs and economic conditions, as noted in the company’s official termination announcement. Since then, NuScale has shifted its strategy toward international partnerships and data center energy requirements. According to the second-quarter 2024 earnings report, the company continues to focus on commercializing its SMR technology while managing its operational expenses.
Comparison of Market Positions
| Feature | Amylyx Pharmaceuticals (AMLX) | NuScale Power (SMR) |
|---|---|---|
| Primary Sector | Biotechnology / Pharmaceuticals | Clean Energy / Nuclear |
| Current Focus | Rare disease drug development | Small Modular Reactor (SMR) technology |
| Key Catalyst | Clinical trial data for AMX0035 | NRC certification and utility contracts |
| Market Status | Post-product withdrawal restructuring | Development and commercialization phase |
Financial and Operational Risks
Investors evaluating these companies must account for fundamentally different risk profiles. Amylyx faces "binary risk," where the success or failure of specific clinical trials directly dictates the company’s value. Clinical drug development is subject to rigorous FDA oversight and the inherent unpredictability of medical research.
NuScale faces "execution risk" and "capital-intensive risk." Building nuclear infrastructure requires long-term capital commitments, complex engineering, and extensive government oversight. The company’s ability to secure long-term power purchase agreements is a critical metric for long-term investors. Both companies remain sensitive to broader macroeconomic factors, such as interest rate changes, which influence the cost of capital for both pharmaceutical R&D and large-scale industrial projects.
Keep reading